IL240555B - Derivatives of hyndatoin and their use as modulators of enzymatic processes - Google Patents
Derivatives of hyndatoin and their use as modulators of enzymatic processesInfo
- Publication number
- IL240555B IL240555B IL240555A IL24055515A IL240555B IL 240555 B IL240555 B IL 240555B IL 240555 A IL240555 A IL 240555A IL 24055515 A IL24055515 A IL 24055515A IL 240555 B IL240555 B IL 240555B
- Authority
- IL
- Israel
- Prior art keywords
- hydantoins
- app processing
- mediated app
- modulate bace
- bace
- Prior art date
Links
- 101150058765 BACE1 gene Proteins 0.000 title 1
- 150000001469 hydantoins Chemical class 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763830P | 2013-02-12 | 2013-02-12 | |
| PCT/US2014/016100 WO2014127042A1 (en) | 2013-02-12 | 2014-02-12 | Hydantoins that modulate bace-mediated app processing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL240555A0 IL240555A0 (en) | 2015-10-29 |
| IL240555B true IL240555B (en) | 2019-02-28 |
Family
ID=51354522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL240555A IL240555B (en) | 2013-02-12 | 2015-08-12 | Derivatives of hyndatoin and their use as modulators of enzymatic processes |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20140371283A1 (OSRAM) |
| EP (2) | EP3653609B1 (OSRAM) |
| JP (2) | JP6471100B2 (OSRAM) |
| KR (2) | KR102220259B1 (OSRAM) |
| CN (1) | CN104995176B (OSRAM) |
| AU (1) | AU2014216390B2 (OSRAM) |
| CA (1) | CA2899938C (OSRAM) |
| DK (1) | DK2956443T3 (OSRAM) |
| ES (2) | ES2769578T3 (OSRAM) |
| IL (1) | IL240555B (OSRAM) |
| WO (1) | WO2014127042A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104995176B (zh) | 2013-02-12 | 2019-02-22 | 巴克老龄化研究所 | 调节bace所介导的app加工的乙内酰脲 |
| KR102220260B1 (ko) | 2015-02-18 | 2021-02-25 | 버크 인스티튜트 포 리서치 온 에이징 | 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘 |
| KR20180090778A (ko) | 2015-08-27 | 2018-08-13 | 난트뉴로, 엘엘씨 | App-선택적 bace 억제를 위한 조성물 및 그의 용도 |
| WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
| NZ751777A (en) * | 2016-08-19 | 2020-08-28 | Foresee Pharmaceuticals Co Ltd | Pharmaceutical composition and methods of uses |
| US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| CN107468690B (zh) | 2017-08-11 | 2020-01-31 | 北京卓凯生物技术有限公司 | 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用 |
| CN107353239B (zh) | 2017-08-11 | 2019-06-18 | 北京卓凯生物技术有限公司 | 4-氧-烷基化特特拉姆酸类化合物及其制备方法 |
| EP3759079A4 (en) * | 2018-03-01 | 2021-11-17 | The Regents Of The University Of California | AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE |
| CN110652516A (zh) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用 |
| CN113412089A (zh) * | 2018-12-04 | 2021-09-17 | 脑部保护私人有限公司 | 包括用于治疗病症的可植入阻尼装置和治疗剂的组合疗法及相关系统和使用方法 |
| CN113727658A (zh) | 2018-12-04 | 2021-11-30 | 脑部保护私人有限公司 | 包括用于治疗病症的可植入阻尼装置和治疗剂的组合疗法及相关系统和使用方法 |
| US11926599B1 (en) | 2023-10-23 | 2024-03-12 | King Faisal University | 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4995971A (OSRAM) | 1973-01-27 | 1974-09-11 | ||
| DE2448869A1 (de) | 1973-10-19 | 1975-09-04 | Mcneilab Inc | 4-oxo-2-imidazolidinylidenharnstoffe, verfahren zu ihrer herstellung und arzneimittel |
| US4025517A (en) | 1975-06-23 | 1977-05-24 | Mcneil Laboratories, Incorporated | 4-Oxo-2-hexahydropyrimidinylidene ureas |
| JPS554305A (en) * | 1978-06-13 | 1980-01-12 | Nippon Zoki Pharmaceut Co Ltd | Remedy for disease caused by stress and its preparation |
| US4864028A (en) * | 1983-09-14 | 1989-09-05 | Alcon Laboratories, Inc. | Spiro-tricyclicaromatic succinimide derivatives |
| US5070100A (en) | 1983-09-14 | 1991-12-03 | Alcon Laboratories, Inc. | Spiro-tricyclicaromatic succinimide derivatives |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| CH677886A5 (OSRAM) | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
| US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
| DK0568575T4 (da) | 1991-01-21 | 2010-12-20 | Elan Pharm Inc | Test og model for Alzheimers sygdom |
| DK0620849T3 (da) | 1992-01-07 | 2003-10-20 | Elan Pharm Inc | Transgene dyremodeller for Alzheimer's sygdom |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| DE69426571T2 (de) | 1993-10-27 | 2001-08-09 | Elan Pharm Inc | TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| FR2730932B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| EP0871720A2 (en) | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| FR2742676B1 (fr) | 1995-12-21 | 1998-02-06 | Oreal | Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie |
| FR2755854B1 (fr) | 1996-11-15 | 1998-12-24 | Oreal | Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations |
| FR2760970B1 (fr) | 1997-03-18 | 2000-03-10 | Oreal | Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations |
| AU5002399A (en) | 1998-07-17 | 2000-02-07 | National Broach And Machine Company | Full form roll finishing technique |
| CA2343004A1 (en) | 1998-09-24 | 2000-03-30 | Pharmacia & Upjohn Company | Alzheimer's disease secretase |
| FR2787027B1 (fr) | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787026B1 (fr) | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787325B1 (fr) | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787326B1 (fr) | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787728B1 (fr) | 1998-12-23 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2787703B1 (fr) | 1998-12-29 | 2001-01-26 | Oreal | Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2788007B1 (fr) | 1999-01-05 | 2001-02-09 | Oreal | Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2788449B1 (fr) | 1999-01-14 | 2001-02-16 | Oreal | Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2789076B1 (fr) | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| US7161962B1 (en) | 1999-05-27 | 2007-01-09 | Nuera Communications, Inc. | Method and apparatus for coding modem signals for transmission over voice networks |
| FR2811564B1 (fr) | 2000-07-13 | 2002-12-27 | Oreal | Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| AU2002241823A1 (en) | 2001-01-11 | 2002-07-24 | Eastman Chemical Company | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials |
| FR2819427B1 (fr) | 2001-01-18 | 2003-04-11 | Oreal | Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| JP2006512401A (ja) | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
| US7476393B2 (en) | 2002-11-29 | 2009-01-13 | L'oreal | Process for the preparation of a cationic nanoemulsion, and cosmetic composition |
| JP4448134B2 (ja) | 2003-08-08 | 2010-04-07 | シェーリング コーポレイション | ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤 |
| AR045219A1 (es) | 2003-08-08 | 2005-10-19 | Pharmacopeia Inc | Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| NZ547462A (en) | 2003-12-15 | 2010-06-25 | Schering Corp | Heterocyclic aspartyl protease inhibitors |
| US7468402B2 (en) | 2004-03-17 | 2008-12-23 | Baker Hughes Incorporated | Polymeric nanoemulsion as drag reducer for multiphase flow |
| EP1743170A2 (en) | 2004-04-02 | 2007-01-17 | Merck & Co., Inc. | Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds |
| US7618978B2 (en) | 2004-04-22 | 2009-11-17 | Eli Lilly And Company | Amides as BACE inhibitors |
| IL162288A0 (en) | 2004-06-01 | 2005-11-20 | Future Products Man S A | Compositions and methods for treating neurodegenerative disorders |
| ES2321853T3 (es) | 2004-06-16 | 2009-06-12 | Wyeth | Difenilimidazopiridina e -imidazol aminas como inhibidores de b-secretasa". |
| ES2332659T3 (es) | 2004-06-16 | 2010-02-10 | Wyeth | Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa. |
| DE602005025363D1 (de) | 2004-07-22 | 2011-01-27 | Schering Corp | Substituierte amide als inhibitoren der beta-sekretase |
| AR050184A1 (es) | 2004-07-28 | 2006-10-04 | Schering Corp | Inhibidores macrociclicos de beta-secretasa |
| PE20060692A1 (es) | 2004-09-21 | 2006-07-19 | Lilly Co Eli | Inhibidores bace |
| EP1851208A1 (en) | 2005-01-13 | 2007-11-07 | Novartis AG | Macrocyclic compounds useful as bace inhibitors |
| GB0500683D0 (en) | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| US7759354B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof |
| WO2006138230A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | The preparation and use of protease inhibitors |
| CA2609582A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| ES2436795T3 (es) | 2005-06-14 | 2014-01-07 | Merck Sharp & Dohme Corp. | Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos |
| KR20080025079A (ko) | 2005-06-14 | 2008-03-19 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
| DE602006018456D1 (de) | 2005-06-14 | 2011-01-05 | Schering Corp | Herstellung und verwendung von verbindungen als aspartylproteasehemmer |
| CN101193892A (zh) | 2005-06-14 | 2008-06-04 | 先灵公司 | 大环杂环天冬氨酰基蛋白酶抑制剂 |
| AU2006266167A1 (en) * | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| WO2007038271A1 (en) | 2005-09-26 | 2007-04-05 | Wyeth | Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
| US7763606B2 (en) | 2005-10-27 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7560451B2 (en) | 2005-10-31 | 2009-07-14 | Schering Corporation | Aspartyl protease inhibitors |
| WO2007058601A1 (en) * | 2005-11-21 | 2007-05-24 | Astrazeneca Ab | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia |
| GB0602951D0 (en) | 2006-02-14 | 2006-03-29 | Novartis Ag | Organic Compounds |
| CN101460480A (zh) | 2006-04-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 |
| GB0611064D0 (en) | 2006-06-05 | 2006-07-12 | Novartis Ag | Organic compounds |
| EP2644600B1 (en) | 2006-06-12 | 2017-01-11 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
| TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
| TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| MX2009000710A (es) | 2006-07-20 | 2009-01-30 | Novartis Ag | Compuestos macrociclicos utiles como inhibidores de bace. |
| CN101484431A (zh) | 2006-07-20 | 2009-07-15 | 诺瓦提斯公司 | 大环内酰胺 |
| BRPI0719336A2 (pt) | 2006-11-23 | 2014-02-04 | Novartis Ag | Derivados de 2-hidróxi-1,3-diaminopropano |
| CA2672293A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors |
| JP2010512390A (ja) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | 三環式系を含むアスパルチルプロテアーゼ阻害剤 |
| TW200831091A (en) * | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| EP2134342B1 (en) | 2007-03-12 | 2013-01-30 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirolactam cgrp receptor antagonists |
| CL2008000784A1 (es) | 2007-03-20 | 2008-05-30 | Wyeth Corp | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| US20090041201A1 (en) | 2007-08-06 | 2009-02-12 | Carestream Health, Inc. | Alignment apparatus for imaging system |
| EP2190833A1 (en) | 2007-08-23 | 2010-06-02 | Novartis Ag | Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
| US20090062361A1 (en) | 2007-08-30 | 2009-03-05 | Allergan, Inc. | Therapeutic hydantoins |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| JP2011527311A (ja) | 2008-07-10 | 2011-10-27 | ノバルティス アーゲー | Ｂａｃｅ阻害薬として有用なアミノベンジル置換環状スルホン誘導体 |
| EP2360155A4 (en) | 2008-10-22 | 2012-06-20 | Shionogi & Co | 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT |
| AP2011005707A0 (en) | 2008-11-11 | 2011-06-30 | Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives. |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| DK2605655T3 (en) | 2010-08-19 | 2019-02-04 | Buck Institute For Age Res | METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS |
| US20120165346A1 (en) | 2010-12-22 | 2012-06-28 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US8877744B2 (en) | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
| CN104995176B (zh) | 2013-02-12 | 2019-02-22 | 巴克老龄化研究所 | 调节bace所介导的app加工的乙内酰脲 |
| KR20180090778A (ko) * | 2015-08-27 | 2018-08-13 | 난트뉴로, 엘엘씨 | App-선택적 bace 억제를 위한 조성물 및 그의 용도 |
-
2014
- 2014-02-12 CN CN201480007825.4A patent/CN104995176B/zh active Active
- 2014-02-12 DK DK14751458.2T patent/DK2956443T3/da active
- 2014-02-12 US US14/179,310 patent/US20140371283A1/en not_active Abandoned
- 2014-02-12 KR KR1020197035067A patent/KR102220259B1/ko active Active
- 2014-02-12 US US14/764,107 patent/US10202355B2/en active Active
- 2014-02-12 WO PCT/US2014/016100 patent/WO2014127042A1/en not_active Ceased
- 2014-02-12 JP JP2015557226A patent/JP6471100B2/ja active Active
- 2014-02-12 ES ES14751458T patent/ES2769578T3/es active Active
- 2014-02-12 CA CA2899938A patent/CA2899938C/en active Active
- 2014-02-12 EP EP19199279.1A patent/EP3653609B1/en active Active
- 2014-02-12 AU AU2014216390A patent/AU2014216390B2/en active Active
- 2014-02-12 EP EP14751458.2A patent/EP2956443B1/en active Active
- 2014-02-12 ES ES19199279T patent/ES2975235T3/es active Active
- 2014-02-12 KR KR1020157021979A patent/KR102051485B1/ko active Active
-
2015
- 2015-08-12 IL IL240555A patent/IL240555B/en active IP Right Grant
- 2015-10-30 US US14/928,775 patent/US9926280B2/en active Active
-
2017
- 2017-12-06 US US15/833,862 patent/US10766867B2/en active Active
-
2019
- 2019-01-17 JP JP2019005905A patent/JP6773820B2/ja active Active
- 2019-02-08 US US16/271,681 patent/US20200017449A1/en not_active Abandoned
-
2020
- 2020-01-10 US US16/740,110 patent/US11091444B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL240555B (en) | Derivatives of hyndatoin and their use as modulators of enzymatic processes | |
| GB2518589B (en) | Image processing | |
| GB201303540D0 (en) | Image processing | |
| GB201318983D0 (en) | Radiotherapy apparatus | |
| GB201307332D0 (en) | Processing system | |
| GB2518949B (en) | Image processing | |
| GB2518950B (en) | Image processing | |
| GB201310597D0 (en) | Audio Processing | |
| SG11201600220XA (en) | Form processing | |
| SG11201601034PA (en) | Photo-alignable object | |
| ZA201600041B (en) | An applicator | |
| GB2514334B (en) | Video processing | |
| GB201316372D0 (en) | Image processing | |
| GB201304872D0 (en) | Treatment | |
| EP2989983A4 (en) | IMAGE PROCESSING DEVICE | |
| GB2511908B (en) | Image processing | |
| GB2516288B (en) | Image processing system | |
| GB201309489D0 (en) | Image processing | |
| GB2514120B (en) | Video processing | |
| GB201317064D0 (en) | Image processing | |
| GB201313111D0 (en) | Lead securing apparatus | |
| GB201312400D0 (en) | Broadcaster | |
| GB201306020D0 (en) | Content processing system | |
| GB2536579B (en) | Pre-composting drum | |
| GB201318486D0 (en) | Clubcrawl app |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |